Altimmune director awarded options for 48,800 shares

Altimmune, Inc. director Diane Jorkasky received a grant of stock options covering 48,800 shares of common stock as board compensation.

Rhea-AI Filing Summary

Altimmune, Inc. director Diane Jorkasky received a grant of stock options covering 48,800 shares of common stock as board compensation. The options carry an exercise price of $2.82 per share and expire on May 1, 2036. The shares underlying the option vest and become exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, conditioned on her continued service as a non-employee director.

Insider Trade Summary

Grant/Award: 48,800 shares

Grant/Award 1 txn

Insider Jorkasky Diane

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (option to buy)	48,800	$0.00	$0.00

Holdings After Transaction: Stock Options (option to buy) — 48,800 contracts (Direct)

Footnotes (2)

1. F1. The options were granted pursuant to the Company's non-employee director compensation policy.
2. F2. The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to the reporting person's continued service through the applicable vesting date.

Key Figures

Stock options granted: 48,800 options Exercise price: $2.82 per share Expiration date: May 1, 2036 +2 more

5 metrics

Stock options granted 48,800 options Grant to director Diane Jorkasky

Exercise price $2.82 per share Exercise price of granted options

Expiration date May 1, 2036 Option expiration

Underlying shares 48,800 shares Common stock underlying the options

Vesting period 12 months Monthly vesting after May 1, 2026

Key Terms

Stock Options (option to buy), non-employee director compensation policy, vested and exercisable, exercise price

4 terms

Stock Options (option to buy) financial

"security_title: Stock Options (option to buy)"

non-employee director compensation policy financial

"The options were granted pursuant to the Company's non-employee director compensation policy."

vested and exercisable financial

"The shares underlying the option become vested and exercisable in substantially equal monthly installments"

exercise price financial

"conversion_or_exercise_price: 2.8200"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Altimmune (ALT) director Diane Jorkasky report in this Form 4 filing?

Director Diane Jorkasky reported receiving a grant of stock options for 48,800 shares of Altimmune common stock. These options are a form of non-employee director compensation and do not represent an open-market purchase or sale of existing shares.

What are the key terms of Diane Jorkasky’s Altimmune stock option grant?

The grant covers 48,800 shares with an exercise price of $2.82 per share and an expiration date of May 1, 2036. The options provide the right, but not the obligation, to buy Altimmune common stock at that price once vested.

How do the Altimmune stock options granted to Diane Jorkasky vest over time?

The options vest and become exercisable in substantially equal monthly installments over 12 months following May 1, 2026. Vesting is subject to Diane Jorkasky’s continued service as a non-employee director through each applicable vesting date.

Is Diane Jorkasky’s Form 4 transaction in Altimmune stock a market trade?

No, the Form 4 shows a compensatory stock option grant, not a market transaction. The options were granted under Altimmune’s non-employee director compensation policy, so no shares were bought or sold on the open market in this filing.

How many Altimmune options does Diane Jorkasky hold after this grant?

Following this transaction, Diane Jorkasky holds 48,800 stock options according to the filing. These options correspond to 48,800 underlying shares of Altimmune common stock, subject to the vesting schedule and the $2.82 per share exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/01/2026 - 04:18 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jorkasky Diane

(Last) (First) (Middle)

910 CLOPPER ROAD

SUITE 201S

(Street)

GAITHERSBURG MARYLAND 20878

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Altimmune, Inc. [ ALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (option to buy)(1)	$2.82	05/01/2026		A		48,800		(2)	05/01/2036	Common Stock, par value $0.0001	48,800	$0	48,800	D

Explanation of Responses:

1. The options were granted pursuant to the Company's non-employee director compensation policy.

2. The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to the reporting person's continued service through the applicable vesting date.

	/s/ Gregory Weaver, as Attorney-in-Fact	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)